Landmark Study in The Lancet: Patients Treated With Betaseron® After First MS Attack Experienced Significant Delay in MS Progres

2008-05-10 アップロード · 24 視聴

Patients treated with Betaseron® (interferon beta-1b) shortly after their first clinical MS event or "attack" showed a 40 percent lower risk of developing confirmed disability progression compared to patients in whom treatment was delayed. The results—which were fast-tracked and published in The Lancet this week—provide the first controlled evidence that delaying Betaseron treatment has an effect on later accumulation of disability, as observed over the three-year study period. No other MS therapy has demonstrated this effect in this early patient population.

The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment. The study was conducted at 98 sites in 20 countries and included a total of 468 patients.

tag·LancetMSBetaseronBENEFITstudyBayerHealthCareMultivu29192

非会員の場合は、名前/パスワードを入力してください。

書き込む
今日のアクセス
98
全体アクセス
143,060
チャンネル会員数
35

My Video

リスト形式で表示 碁盤形式で表示

02:43

공유하기
iPods: Careful What You Keep!
9年前 · 59 視聴